metastatic colorectal cancer

Tucatinib Plus Trastuzumab approved for wild-type RAS, unresectable HER2+ or metastatic CRC

The FDA on Thursday granted accelerated approval for tucatinib (Tukysa) when given with trastuzumab to treat adults with RAS wild-type, metastatic or unresectable HER2-positive colorectal cancer (mCRC) that progresses after treatment with specific types of chemotherapy. Approval of this chemotherapy-free combination is based on results from the phase 2 MOUNTAINEER trial (NCT03043313), which found an […]

Scroll to top